What is the current price and recent volume for GV.PA stock?

GV.PA stock closed at **€0.0018** on 20 Mar 2026. Volume that session was **38,489,238** shares, roughly 2.71 times the average daily volume, indicating heavy intraday trading and elevated short-term volatility.

What is Meyka AI’s grade and recommendation for GV.PA stock?

Meyka AI rates GV.PA with a score out of 100: **62.50 | Grade: B | Suggestion: HOLD**. The grade combines sector comparison, financial metrics and forecasts; it is informational and not financial advice.

What is the 12-month forecast and implied upside for GV.PA stock?

Meyka AI's forecast model projects a 12-month target of **€0.005**, compared with the current price of **€0.0018**, implying an upside of **177.78%**. Forecasts are projections and not guarantees, subject to dilution and execution risk.

What are the main risks for investors in GV.PA stock?

Primary risks for GV.PA stock include negative equity, recurring operating losses, potential equity dilution, low market cap (**€693,191**) and thin trading depth. These magnify price swings and raise funding uncertainty for continued R&D and commercialization.

EU Stocks

Genomic Vision (GV.PA) EURONEXT closes at €0.0018 on 20 Mar 2026: heavy volume signals volatility

ByDanny Kontos March 20, 2026March 20, 2026

Genomic Vision SA (GV.PA) was one of the most active names on EURONEXT today, closing at €0.0018 on 20 Mar 2026 after 38,489,238 shares traded. Volume was 2.71x the average, driving a +5.88% intraday move from €0.0017. GV.PA stock remains a high-volatility small-cap in the Healthcare diagnostics space, with a market cap of €693,191 and a sharply negative year-to-date trend. Below we analyse trading, fundamentals, technicals, a Meyka AI grade and a model forecast to frame near-term risk and opportunity.